Product Support & Resources

For eligible, commercially insured patients,

Get your patients started with the Emgality savings carda

Patients can get Emgality FREE for up to 12 months

Savings Card Equation image

Help eligible patients save on Emgality—download savings card(s) now

aTerms and Conditions: Offer good for up to 12 months until 12/31/2020 if healthcare provider submits a prior authorization form or coverage exception request, when required, to the patient’s insurance provider. $0 monthly offer for commercially insured with insurance provider coverage, subject to wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual cap. $0 monthly offer for commercially insured without insurance provider coverage, subject to monthly and separate annual cap of wholesale acquisition cost plus usual and customary pharmacy charges. This offer is not available for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by Medicare Part D, Medicaid, TRICARE, or any other state or federal program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

Other product/company names mentioned herein are the trademarks of their respective owners.

Emgality Loading Dose Kit (sample)

The Loading Dose Kit (sample) provides patients a chance to administer the first month of Emgality in office. Loading Dose Kits (samples) are intended to assess safety and efficacy for patients in the office

If interested in requesting Emgality Loading Dose Kits (samples), call 1-833-EMGALITY (1-833-364-2548) Mon-Fri, 9am to 8pm ET.

Learn more

Want to learn about Emgality?

Register here to receive updates from Lilly.

Indication and Important Safety Information

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.